Patient characteristics
| Characteristic | Phase I (n=20) | Phase II (n=80) | |||
| Pembrolizumab with concurrent SBRT (n=19) | Pembrolizumab (salvage SBRT if applicable) (n=21) | Pembrolizumab with concurrent traditional RT (n=21) | Pembrolizumab (salvage traditional RT if applicable) (n=19) | ||
| Sex | |||||
| Male | 13 (65) | 13 (68) | 16 (76) | 13 (62) | 9 (47) |
| Female | 7 (35) | 6 (32) | 5 (24) | 8 (38) | 10 (53) |
| Median age, years (range) | 65 (33-79) | 68 (52-81) | 70 (52-85) | 63 (44-91) | 63 (52-77) |
| Histology | |||||
| Adenocarcinoma | 16 (80) | 15 (79) | 16 (76) | 17 (80) | 13 (68) |
| SCC | 4 (20) | 4 (21) | 5 (24) | 2 (10) | 6 (32) |
| NSCLC, NOS | 0 | 0 | 0 | 2 (10) | 0 |
| Ethnicity | |||||
| White | 19 (95) | 15 (79) | 17 (80) | 18 (85) | 16 (84) |
| Black | 0 | 2 (11) | 2 (10) | 1 (5) | 3 (26) |
| Asian | 1 (5) | 1 (5) | 2 (10) | 2 (10) | 0 |
| Other | 0 | 1 (5) | 0 | 0 | 0 |
| Smoking status | |||||
| Current/former | 14 (70) | 13 (68) | 16 (76) | 17 (80) | 15 (79) |
| Never smoker | 6 (30) | 6 (32) | 5 (24) | 4 (20) | 4 (21) |
| Prior therapy (<6 months) | |||||
| Radiation | 3 (15) | 5 (26) | 4 (20) | 3 (15) | 3(16) |
| Chemotherapy | 10 (50) | 7 (37) | 5 (24) | 8 (38) | 7 (37) |
| Immunotherapy | 0 | 1 (5) | 0 | 1 (5) | 0 |
| Oligometastatic disease (<3 lesions) | 18 (90) | 17 (89) | 18 (85) | 14 (67) | 16 (84) |
| Completed RT | 20 (100) | 16 (84) | 6 (29) | 20 (95) | 1 (5) |
| Site of RT | |||||
| Lung | 18 (90) | 17 (89) | 20 (95) | 21 (100) | 19 (100) |
| Liver | 2 (10) | 2 (11) | 1 (5) | 0 | 0 |
| Cycles of pembrolizumab | 8 (1-16) | 10 (1-16) | 9 (1-19) | 7 (1-16) | 6 (1-16) |
| Driver mutations | |||||
| EGFR+ | 1 (11) | 3 (21) | 3 (19) | 3 (20) | 2 (13) |
| P53+ and Kras+ | 0 | 3 (21) | 2 (12) | 3 (20) | 1 (6) |
| Kras+ and STK11+ | |||||
| PD-L1 status | |||||
| <1% | 4 (20) | 4 (21) | 5 (24) | 5 (24) | 5 (26) |
| 1-49% | 2 (10) | 6 (31) | 3 (14) | 7 (33) | 3 (16) |
| >50% | 3 (15) | 2 (11) | 4 (19) | 2 (9) | 5 (26) |
| Not available | 11 (55) | 7 (37) | 9 (43) | 7 (34) | 6 (32) |
Data are median (IQR) or percentages.
NOS, not otherwise specified; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; RT, radiotherapy; RT, radiotherapy; SBRT, stereotactic body RT; SCC, squamous cell carcinoma.